 "HC asks Singh brothers to reply to Daiichi plea")
Japanese pharma firm Daiichi Sankyo approached Delhi high court once again on Tuesday, to block former Ranbaxy promoters Malvinder Singh and Shivinder Singh from selling their stake in Fortis Healthcare.
The court asked the Singh brothers to file a reply before Monday, when next hearing will take place. In its application, Daiichi claimed that the Singh brothers have failed to file details of their debt-free assets in the correct format, as directed by the court on January 23.
Daiichi had approached the Delhi high court last year, seeking enforcement of a Rs 2,562-crore Singapore arbitration award against the Singh brothers, as well as asking for an additional Rs 1,000 crore for interest payments and lawyers fees incurred during arbitration proceedings.
The April 2016 arbitration award came after Daiichi sued the Singh brothers for allegedly concealing and misrepresenting critical information on proceedings by US agencies before selling their majority stake in Ranbaxy to the Japanese company. It cost Daiichi $500 million to settle up with the US agencies in 2013.
In its January 23 order, the high court had allowed Daiichi access to asset declarations by Singh brothers for use in judicial proceedings, subject to an affidavit of confidentiality being filed by the Japanese company.
The court asked the Singh brothers to file a reply before Monday, when next hearing will take place. In its application, Daiichi claimed that the Singh brothers have failed to file details of their debt-free assets in the correct format, as directed by the court on January 23.
Daiichi had approached the Delhi high court last year, seeking enforcement of a Rs 2,562-crore Singapore arbitration award against the Singh brothers, as well as asking for an additional Rs 1,000 crore for interest payments and lawyers fees incurred during arbitration proceedings.
The April 2016 arbitration award came after Daiichi sued the Singh brothers for allegedly concealing and misrepresenting critical information on proceedings by US agencies before selling their majority stake in Ranbaxy to the Japanese company. It cost Daiichi $500 million to settle up with the US agencies in 2013.
In its January 23 order, the high court had allowed Daiichi access to asset declarations by Singh brothers for use in judicial proceedings, subject to an affidavit of confidentiality being filed by the Japanese company.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%